Please assess the completion status of the following clinical trial:

Trial Title: Study of NPF-08 in Patients Who Receive Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Japanese men and women aged 20 years or older at obtaining the written informed consent.~2. Patients who require colonoscopy (except for emergency colonoscopy)~3. Patients who have the ability to consent and submit the written informed consent by themselves.~Exclusion Criteria:~1. Patients who have or are suspected to have gastrointestinal obstruction.~2. Patients who have or are suspected to have intestinal perforation.~3. Patients who have or are suspected to have toxic megacolon.~4. Patients who have or are suspected to have gastric evacuation disorder (gastroparesis).~5. Patients with intestinal stenosis or high-grade constipation (stool frequency of 2 or less in a week or who have used laxative on a daily basis).~6. Patients with vomiting reflex or in whom accidental ingestion may occur.~7. Patients with a history of gastrointestinal surgery (except for appendicectomy).~8. Patients who were decided as glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.~9. Patients with renal impairment (urea nitrogen: 25mg/dL or more, or creatinine: 2mg/dL or more)~10. Patients with hepatic dysfunction (total bilirubin: 3.0mg/dL or more, ALT: 100IU/L or more or AST: 100IU/L or more)~11. Patients who have undergone or require therapy due to high-grade cardiac disease (including angina pectoris or myocardial infarction)~12. Patients with high risk of arrhythmia (with a history or complications of QT prolongation, myocardial infarction, angina pectoris, cardiac failure or cardiomyopathy)~13. Patients with dehydration.~14. Patients who were diagnosed with active inflammatory bowel disease at screening period.~15. Inpatients due to the reasons other than endoscopy large bowel.~16. Patients who have undergone nutritional control using total parenteral nutrition or enteral nutrition.~17. Women who are or may be pregnant, lactating or wish to become pregnant during the trial period.~18. Patients with a history or high-risk of seizure.~19. Patients with a history of shock or hypersensitivity for the active ingredient of the investigational product.~20. Patients who have received the other investigational product within 4 months before the written informed consent or who are participating in the other clinical trials.~21. Patients in whom Investigator/Sub-Investigator decided not to be eligible for this trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NPF-08 （1-day treatment） (Type: EXPERIMENTAL): None
- NPF-08 （2-day split dose） (Type: EXPERIMENTAL): None
- Moviprep（1-day treatment） (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).